Oncology Institute (DFPH) Cost of Revenue (2021 - 2026)

Oncology Institute (DFPH) has 6 years of Cost of Revenue data on file, last reported at $8.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 73.65% year-over-year to $8.3 million; the trailing twelve-month figure through Mar 2026 stood at $74.9 million (up 881.52% YoY), and the FY2025 full-year result was $220.6 million, up 16813.96% from the prior year.
• Cost of Revenue for Q1 2026 stood at $8.3 million, down from $66.5 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $66.5 million in Q4 2025 and bottomed at -$110.4 million in Q4 2024.
• The 5-year median for Cost of Revenue is $34.5 million (2022), against an average of $22.5 million.
• The widest annual swing landed in 2023, when Cost of Revenue soared 40886.44%; it then sank 328.26% in 2024.
• A 5-year view of Cost of Revenue shows it stood at $118000.0 in 2022, then jumped by 40886.44% to $48.4 million in 2023, then sank by 328.26% to -$110.4 million in 2024, then jumped by 160.27% to $66.5 million in 2025, then plunged by 87.56% to $8.3 million in 2026.
• The last three Cost of Revenue figures came in at $8.3 million (Q1 2026), $66.5 million (Q4 2025), and $65000.0 (Q2 2025), per Business Quant data.

Peer Comparison